Use of hR3 MaB and radiotherapy in treatment of patients with highly malignant astrocytic tumors, phase III

Trial Profile

Use of hR3 MaB and radiotherapy in treatment of patients with highly malignant astrocytic tumors, phase III

Completed
Phase of Trial: Phase III

Latest Information Update: 09 Mar 2017

At a glance

  • Drugs Nimotuzumab (Primary)
  • Indications Anaplastic astrocytoma; Glioblastoma; Glioma
  • Focus Biomarker; Registrational; Therapeutic Use
  • Sponsors YM BioSciences
  • Most Recent Events

    • 31 Jul 2013 Status changed from active, no longer recruiting to completed as reported by Cuban Clinical Trial Registry.
    • 02 Jun 2012 Results presented at the 48th Annual Meeting of the American Society of Clinical Oncology.
    • 03 Nov 2008 A total of 65 patients (all with glioblastoma) have been enrolled as of the 3rd Nov 2008, according to a YM Biosciences media release
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top